It is worth noting that a case report has documented the development of myopathy symptoms and elevated blood CPK levels in a patient with Crohn’s disease following an adjustment in daily upadacitinib dosage from 30 mg to 45 mg for 1 week. This evidence concerns the gene PIK3C2A and myopathy.